HCM - Why HUTCHMED Stock Is Moving Higher Friday | Benzinga
HUTCHMED (NASDAQ:HCM) stock is trading higher on Friday following the company’s announcement that its New Drug Application (NDA) for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.
The Details: The China National Medical Products Administration granted priority review for the treatment for certain types of lymphoma. The NDA is based on a Phase 2 study in China and clinical trials conducted by Epizyme outside of China.
Tazemetostat is already approved ...